Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Austria (REAL)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 May 2017
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms REAL
- Sponsors AbbVie
- 15 Aug 2016 Planned End Date changed from 1 Jan 2017 to 1 Jul 2017.
- 15 Aug 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jul 2017.
- 13 Jun 2016 Status changed from recruiting to active, no longer recruiting.